"Federal prohibition of psychedelic medicine in America is over" — Trump signs psychedelics EO, and the cannabis industry is watching
Trump's April 18 executive order ships $50M in ARPA-H funding, three FDA Priority Vouchers within a week, and the first-ever U.S. ibogaine IND clearance. Inside the order's five sections, the Oval Office cast, and why the cannabis industry — still waiting on the rescheduling order Trump signed four months ago — is measuring every word of this one.
President Donald Trump signed an executive order on Saturday in the Oval Office titled "Accelerating Medical Treatments for Serious Mental Illness," directing the FDA, DEA, HHS, and the Department of Justice to fast-track psychedelic therapies — including ibogaine, psilocybin, and MDMA — through research, clinical trials, and scheduling review.
The ceremony was staged with the supporting cast of a political movement: HHS Secretary Robert F. Kennedy Jr., FDA Commissioner Dr. Marty Makary, Rep. Morgan Luttrell (R-TX), and podcaster Joe Rogan. Veterans Affairs Secretary Doug Collins was present but did not speak.
Trump framed the order as both a veterans' health initiative and a regulatory shakeup.
"This will dramatically accelerate access to new medical research and treatments based on psychedelic drugs," Trump said. "In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression — including our cherished veterans."
The order runs to five sections. Here's what it actually does — and why the cannabis industry is watching every word of it.
What the order does
Section 1 — Purpose. The order opens with the statistics: 14 million Americans living with serious mental illness, suicide rates up 37% between 2000 and 2018, veteran suicide rates more than twice the general population. It names psychedelics as "showing clinical promise" for treatment-resistant conditions and credits the first Trump administration with bending the suicide curve before it rebounded.
Section 2 — FDA Priority Vouchers and Right to Try. This is the core mechanism. The FDA Commissioner is directed to issue Commissioner's National Priority Vouchers (CNPVs) to psychedelic drugs holding Breakthrough Therapy designation. CNPVs compress standard New Drug Application review timelines from roughly 10–12 months to 1–2 months. For reference: Eli Lilly's weight-loss drug received approval in 50 days under a Priority Voucher.
The FDA and DEA are further directed to establish pathways for eligible patients to access Schedule I psychedelics under the federal Right to Try Act, which allows patients with life-threatening illnesses who have exhausted other options to receive investigational drugs. Making a Schedule I substance Right-to-Try-eligible is a structural change — until now, Schedule I status has effectively walled these drugs off from the program.
Section 3 — $50 million for state programs. HHS is directed to allocate a minimum of $50 million from its Advanced Research Projects Agency for Health (ARPA-H) to match state investments in psychedelic treatment programs. The money draws from ARPA-H's existing $100 million EVIDENT initiative, launched in November 2025 to develop objective mental health measures and rapid-acting therapeutics.
Section 4 — VA and private sector data sharing. HHS and the FDA are directed to collaborate with the Department of Veterans Affairs and private sector partners to increase clinical trial participation and data sharing for Breakthrough-designated psychedelics.
Section 5 — Timely rescheduling. The Attorney General, in consultation with HHS, is directed to review and complete rescheduling of Schedule I substances that successfully complete Phase 3 trials for serious mental health disorders.
That last section is where the cannabis industry sat up.
The ibogaine breakthrough
During the ceremony, FDA Commissioner Marty Makary made a separate announcement with considerable operational weight: the first-ever ibogaine Investigational New Drug (IND) clearance in the United States.
Ibogaine — a psychoactive alkaloid derived from the West African iboga plant — has been used for decades in unregulated clinics in Mexico, Costa Rica, and elsewhere, often by U.S. veterans traveling abroad to treat PTSD, addiction, and traumatic brain injury. Stanford researchers published a 2024 study in Nature Medicine showing significant reductions in disability ratings and suicidal ideation among special-operations veterans treated with magnesium-ibogaine therapy. Until Saturday, the compound had no legal pathway to U.S. clinical trials.
The IND clearance opens that pathway.
"Drugs can get approved in weeks — not a year or a year plus, but in weeks," Makary said.
Bryan Hubbard, CEO of Americans for Ibogaine, was blunter in his reaction: "Federal prohibition of psychedelic medicine in America is over."
Rep. Luttrell, a former Navy SEAL who has spoken publicly about his own ibogaine treatment, said at the ceremony: "It changed my life, and I look forward to seeing the impact it will have on countless others. We're losing too many veterans. If this treatment gives us a chance to change that, then we owe it to them."
Joe Rogan, whose platform has arguably done more than any single actor to mainstream psychedelic therapy discourse in the United States, offered the shortest speech: "For 56 years we've lived under those terrible conditions. We're free of that now."
The Breakthrough Therapy pipeline
The EO's Priority Voucher mechanism is only as powerful as the pipeline of drugs it can accelerate. As of April 2026, the psychedelic companies most immediately positioned to benefit include:
- Compass Pathways — psilocybin (COMP360) for treatment-resistant depression, Phase 3 trials ongoing
- Resilient Pharmaceuticals — MDMA for PTSD, following Lykos Therapeutics' 2024 rejection
- Lykos Therapeutics — continuing MDMA-assisted therapy research after FDA required additional Phase 3 data
- Americans for Ibogaine / atai Life Sciences — ibogaine analogs and derivatives
- MindMed — LSD-based compound MM120 for generalized anxiety disorder
RFK Jr. confirmed the administration will issue three Priority Vouchers to psychedelic candidates within a week, with additional vouchers available for Breakthrough-designated drugs that meet program criteria.
"We're taking this decision to confront one of the most urgent public health challenges facing our nation, the mental health crisis," Kennedy said. "We're expanding the use of Right to Try, so that eligible patients with treatment-resistant conditions can access these therapies."
Why the cannabis industry is watching
Trump's psychedelics EO comes four months to the day after his December 18, 2025 executive order directing the Attorney General to "expeditiously" reschedule marijuana from Schedule I to Schedule III. The cannabis order has produced no movement. No new administrative law judge has been appointed. The DEA confirmed in an April 10 filing that the marijuana rescheduling appeal process "remains pending."
At the psychedelics signing ceremony, Trump departed from the script to make that contrast explicit — and uncomfortable.
"You're going to get the rescheduling done, right, please?" Trump said, according to reporting from the event.
The president publicly complained that his own Department of Justice is "slow-walking" marijuana rescheduling. Four months after signing the order to make it happen.
The structural parallels between the two EOs are hard to miss:
| Mechanism | Psychedelics EO (April 2026) | Cannabis EO (December 2025) | |---|---|---| | Rescheduling directive | AG + HHS review after Phase 3 | AG + DEA expeditious process | | Funding | $50M ARPA-H match | None | | FDA fast-track | Priority Vouchers | None | | Patient access | Right to Try expansion | None | | Timeline to action | Three vouchers in one week | Four months, no movement |
The psychedelics order ships with funding, regulatory tooling, and an immediate operational announcement (the ibogaine IND). The cannabis order shipped with a directive and nothing else.
Industry observers have noted the DOJ's posture on cannabis is not the DEA's posture on psychedelics. Attorney General Pam Bondi, a former Florida AG and longtime opponent of marijuana legalization, has made no public statements on rescheduling since taking office. A Trump advisor told Marijuana Moment earlier this month that someone in the administration is "holding up" cannabis rescheduling.
What's different about psychedelics? Three things:
-
Political coalition. Psychedelics have built a bipartisan veteran-focused coalition that cannabis rescheduling never fully assembled. Rep. Luttrell on the right, veterans service organizations, and figures like Rick Perry have sustained a Republican-friendly narrative that cannabis politics struggled to match.
-
Framing. The psychedelics EO is framed as a mental health intervention. The cannabis EO is framed as a scheduling correction. Mental health has fewer political enemies than "drug policy."
-
Pipeline. Psychedelics have a clean FDA pipeline with well-funded sponsors. Cannabis rescheduling has no equivalent sponsor — it's the entire industry, which means it's no single industry actor.
What happens next
Within one week: FDA issues three Priority Vouchers to Breakthrough-designated psychedelic candidates.
Near-term: Ibogaine IND opens the door to the first U.S.-based clinical trials on the compound, likely at academic medical centers and VA facilities.
Mid-term (6–18 months): Phase 3 results from Compass, Resilient, and others will test the Section 5 rescheduling mechanism. If a psychedelic clears Phase 3 and is rescheduled faster than cannabis — which began its rescheduling process in August 2023 — the embarrassment for the administration's cannabis posture becomes acute.
Longer-term: The $50M ARPA-H match fund will slot into state-level ibogaine research programs in Kentucky, Texas, and other states that have already allocated state dollars. Texas alone has authorized $50 million in state matching funds for ibogaine trials.
The bottom line
Trump's psychedelics executive order is the most aggressive federal action on Schedule I substances in fifty years. It moves money, moves the FDA, moves the DEA, and ships with an operational announcement that clears the way for the first legal ibogaine trials in U.S. history.
It also sets a standard the cannabis industry will measure its own executive order against. The president spent part of Saturday's ceremony publicly asking his own DOJ when they plan to get around to the order he signed four months ago.
Everyone in the Oval Office heard it. The DOJ heard it. And everyone who owns a cannabis license, runs a dispensary, or files a cannabis-related tax return heard it.
The question now is who in this administration is still listening.